Lynparza recommended for approval in ovarian cancer

View source ↗

Summary

The EMA recommends approving Lynparza (olaparib) for ovarian cancer, indicating potential new treatment option pending final authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)